Skip to main content

Table 1 Baseline clinical characteristics for all patients

From: Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis

  RA
(n = 64)
PsA
(n = 29)
AS
(n = 20)
MTX
(n = 49)
anti-TNF ± MTX
(n = 64)
Age (years) 57 (28–79) 50 (23–78) ¥ 49 (30–72) ф 56 (28–79) 55 (23–75)
Women, n (%) 47 (73) 12 (41) ¥ 4 (20) ɸ€ 30 (61) 33 (52)
Rheumatic disease duration (years) 2 (0–30) 3 (0–37) 3 (0–40) 0.10 (0–25) 3.7 (0–40)*
Disease activity
 CRP (mg/L) 8 (1–78) 5 (1–99) 10 (1–157) 8 (1–99) 6.5 (1–157)
 ESR (mm/h) 18.5 (1–81) 7 (2–48) ¥ 9.5 (2–87) ɸ 14 (1–81) 13 (2–87)
 Anti-CCP, n (%) 39 (61) 17 (35) 22(34)
 Rheumatoid factor IgA, n (%) 32 (50) 15 (31) 17 (27)
 Rheumatoid factor IgM, n (%) 45 (70) 22(45) 23(36)
 BASDAI 4.73 (0.3–9.5) 5.1 (0.9–9.6) 5.5 (0.3–9.3) 5.1 (0.9–9.7)
 BASFI 3.2(0–9) 4.1 (1.1–7.6) 3.0 (0–9) 3.8 (0.4–8.6)
 BASMI 3 (0–10) 3 (0–10)
 DAS28 4.98 (2.6–7.3) 5.2 (3.1–7.3) 5.1(2.6–7.1)
 PtGA 52 (5–98) 44 (2–96) 56 (6–96) 52 (2–96) 49 (6–98)
 PGA 38 (7–73) 21 (0–57) ¥ 26 (3–60) ф 38 (11–73) 27(0–73)*
 MHAQ 0.65 (0–1.45) 0.40 (0.05–1.55) 0.43 (0–1.40) 0.45 (1–1.55) 0.50 (0–1.40)
Treatment, n (%)
 Anti-TNF monotherapy 0 (0) 4 (14) ¥ 20 (100) ɸ€ 0 24 (38)*
 MTX monotherapy 34 (53) 15 (52) 0 (0) ɸ€ 49 (100) 0 (0)*
 Anti-TNF ± MTX 30 (47) 10 (34) 0 (0) ɸ€ 0 (0) 40 (62)*
 Beta-blockers 5 (8) 1 (3) 4 (20) 4 (8) 6 (9)
 Calcium antagonists 5 (8) 2 (7) 2 (10) 2 (4) 7 (11)
 ACE inhibitors 6 (9) 1 (3) 2 (10) 4 (8) 5 (8)
 NSAIDs 47 (73) 14 (48) ¥ 14 (70) 35 (71) 40 (62)
 Coxibs 0 (0) 0 (0) 1 (5) 0 (0) 1 (2)
 Statins 12 (19) 1 (3) ¥ 7 (35) 7 (14) 13 (20)
 Acetyl salicylic acid 6 (9) 2 (7) 3 (15) 6 (12) 5 (8)
 Warfarin 0 (0) 0 (0) 1 (5) 0 (0) 1 (2)
 Glucocorticoids 17 (27) 3 (10) ¥ 2 (10) ɸ 8 (16) 15 (23)*
  1. Unless indicated otherwise, values are given as median (range)
  2. Statistically significant differences are shown in bold typeface
  3. *P < 0.05, versus MTX
  4. ¥ P < 0.05, versus RA
  5. P < 0.05, versus PsA
  6. Ф P < 0.05, versus RA
  7. ACE angiotensin converting enzyme, anti-TNF antitumor necrosis factor, AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DAS28 Disease activity score for 28 joints, ED endothelial dysfunction, ESR erythrocyte sedimentation rate, Ig immunoglobulin, MHAQ Medical Health Assessment Questionnaire, MTX methotrexate, NSAID nonsteroidal anti-inflammatory drug, NSJ number of swollen joints, PGA Physicians' Global Assessment Score of Disease Activity, PsA psoriatic arthritis, PtGA Patients' Global Assessment Score of Disease Activity, RA rheumatoid arthritis, RHI Reactive Hyperemic Index, WBC white blood cell